Try our Advanced Search for more refined results

Expert Analysis

Case Study: In Re Rigel Pharma Securities Litigation

Law360, New York (September 25, 2012, 2:21 PM EDT) -- On Sept. 6, 2012, the United States Court of Appeals for the Ninth Circuit issued a decision in In re Rigel Pharmaceutical Securities Litigation, No. 10-17619, which addressed the question of "whether statements concerning statistical results of a clinical trial may be considered false or misleading under Rule 10b-5 because the statistical methodology that produced those results was not the best or most acceptable methodology." The court answered in the negative, holding that allegations that a pharmaceutical company used an imperfect methodology to present its clinical trial results were insufficient to plead securities law violations....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!